Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Improving Memory in Patients With Multiple Sclerosis

This study has been withdrawn prior to enrollment.
(Study terminated/withdrawn)
Sponsor:
Collaborator:
U.S. Department of Education
Information provided by:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
ClinicalTrials.gov Identifier:
NCT00062972
First received: June 18, 2003
Last updated: May 20, 2011
Last verified: May 2011

June 18, 2003
May 20, 2011
September 1999
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00062972 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Improving Memory in Patients With Multiple Sclerosis
Interventions to Improve Memory in Patients With Multiple Sclerosis

People with multiple sclerosis (MS) suffer from cognitive and other brain problems. This study will examine the effectiveness of the drug donepezil and of sugar water for enhancing memory in individuals with MS. Donepezil (also known as Aricept) has been FDA approved for improving memory and learning in individuals with Alzheimer's disease.

Cognitive dysfunction is one of the leading causes of disability in people with MS. Memory involving specific words (verbal memory) is particularly affected in individuals with MS. Attempts to rehabilitate cognitive dysfunction in MS have had only limited success.

This study will determine the efficacy of donepezil therapy and glucose administration for enhancing verbal memory functioning in individuals with MS. The study will also measure secondary outcomes assessing other areas of cognitive dysfunction (i.e., nonverbal memory, conceptual thinking, processing speed) which may improve with intervention.

Forty participants with MS will be randomly assigned to receive either donepezil or placebo for 24 weeks. Participants will complete memory and cognitive tests at the beginning and end of the 24 week period.

Twenty participants with MS will be randomly assigned to drink a beverage sweetened with either glucose or saccharin (placebo). Participants will then complete memory and other cognitive tests. Two weeks later, participants will drink a beverage sweetened with the alternative sweetener and again complete the memory and cognitive tests.

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Multiple Sclerosis
  • Drug: donepezil
  • Drug: glucose
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Withdrawn
60
August 2002
Not Provided

Inclusion Criteria

  • MS as defined by the Poser criteria
  • Expanded Disability Status Scale (EDSS) score of 0 to 6.5
  • Stable neurologic function for at least 30 days prior to study entry
  • Agree to continue all current medications for study duration
  • Rey Auditory Verbal Learning Test score in low normal range or below
  • Mini-mental status exam score of 26 or higher
  • Montgomery-Asberg Depression Scale scaled score of 14 or lower
  • Fluent in English

Exclusion Criteria

  • Use of anticholinergic or benzodiazepine medication
  • Change in dosage of medications judged to have the potential to impact cognitive function (e.g., antispasticity medications) within 2 weeks of study entry
  • Current alcohol or substance abuse
  • History of neurological or major medical problem that has a known effect on cognitive functioning
  • History of noncompliance
  • Visual or upper extremity impairment which precludes ability to participate in cognitive assessment
Both
18 Years to 56 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00062972
1R01 HD38107-01
Not Provided
Not Provided
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
U.S. Department of Education
Principal Investigator: Lauren B. Krupp, MD Department of Neurology, University Hospital Medical Center
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
May 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP